On February 4, 2026, Citigroup analysts raised their recommendation on Bio-Techne Corporation (TECH) to a Buy, reflecting renewed confidence in the company’s growth trajectory. In conjunction with the upgrade, Citigroup increased its 12-month price objective by more than 14%, signaling expectations for continued upside driven by Bio-Techne’s leading position in life-sciences reagents and diagnostics. This marks the second target increase in six months, underscoring the firm’s view that stable end-markets and solid execution will translate into stronger returns for shareholders over the coming year.

For the quarter ended December 31, 2025, Bio-Techne reported revenue of $295.9 million, flat on both a reported and organic basis versus prior year, despite currency tailwinds of 2% offset by a 2% non-recurring revenue adjustment from a held-for-sale business. GAAP operating income rose 15% to $54.5 million, lifting GAAP operating margin to 18.4%, a 240-basis-point improvement over the year-ago period. On a non-GAAP basis, adjusted operating income climbed to $92.0 million, delivering a 31.1% margin, up 100 basis points. Adjusted EPS of $0.46 beat the year-ago $0.42, driven by productivity initiatives and the divestiture of the Exosome Diagnostics unit. Segment breakdown showed Protein Sciences net sales of $215.1 million (up 2% reported) with a 39.3% margin, while Diagnostics & Spatial Biology contributed $81.2 million (down 4% reported) and expanded its margin to 10.4%.

On February 4, 2026, Bio-Techne’s Board approved a quarterly dividend of $0.08 per share, payable February 27 to shareholders of record on February 16. This marks the 14th consecutive quarterly payout, reflecting the company’s confidence in generating sustained free cash flow. With a market capitalization exceeding $10.7 billion and over $1.2 billion in net sales for fiscal 2025, Bio-Techne continues to balance reinvestment in R&D and bolt-on acquisitions alongside returning capital to shareholders.